AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
88.99
-0.56 (-0.63%)
At close: Nov 19, 2025, 4:00 PM EST
90.06
+1.07 (1.20%)
Pre-market: Nov 20, 2025, 5:18 AM EST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.74
Revenue / Employee
$625,694
Employees
92,900
Market Cap
275.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
AZN News
- 1 day ago - Why biotech and drug stocks are on the mend even though the rest of the market is hurting - Market Watch
- 1 day ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 5 days ago - Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes - Reuters
- 8 days ago - FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines - Reuters
- 9 days ago - AstraZeneca hits record high, cements lead as UK's biggest stock - Reuters
- 9 days ago - AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial - Benzinga
- 10 days ago - Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial - Business Wire
- 12 days ago - Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease - Business Wire